Additional file 1: Figure S1. of Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials

Quality assessment. (A) Risk of bias summary. (B) Risk of bias graph. (PPTX 76 kb

Additional file 2: Figure S2. of Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials

Effect of PDE5i on BP and HR. Forest plot of the pooled weighted mean differences of (A) SBP (mmHg), (B) DBP (mmHg), (C) MAP (mmHg), and (D) HR (beat per minute). Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate. Figure S3. Effect of PDE5i on cardiac performance. Forest plot of the pooled weighted mean differences of (A) cardiac index (L/min/m2), and (B) cardiac output (L/min). (TIF 5850 kb

Additional file 3: Figure S4. of Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials

Influence analysis for the RCTs of HFpEF. Sensitivity analysis was performed to assess the potential influence of each RCT to the effect size of the RCTs of HFpEF. Pooled effects of PDE5i when each RCT was omitted were shown for (A) LVEF (%), (B) mPAP (mmHg), (C) PASP (mmHg), and (D) PVR (dyn¡sec/cm5). The omission of the study by Guazzi M et al. [12] significantly changed the pooled effect size of PDE5i, suggesting that there was a substantial influence from the study by Guazzi M et al. on the overall outcome measures. Abbreviations: RCT, randomized controlled trial; HFpEF, heart failure with preserved ejection fraction; PDE5i, phosphodiesterase type 5 inhibitor; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PVR, pulmonary vascular resistance. (PPTX 588 kb

Additional file 1: of Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial

SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOCX 48 kb

Additional file 2: of Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial

Supplementary methods for details of imaging protocols. (DOCX 26 kb

CONSORT diagram of the study population selection.

<p>CCTA, coronary computed tomographic angiography; SPECT, single-photon emission computed tomography; CAD, coronary artery disease.</p

Kaplan-Meier survival curves for adverse cardiac events from combined cardiac CT and SPECT information.

<p>Event-free survival curves stratified by (A) coronary artery calcium score (CACS) of 400 and presence or absence of perfusion defect (PD), (B) diameter stenosis (DS) of 50% and presence or absence of PD, (C) presence of plaque in 3 or more segments of the coronary tree and presence or absence of PD, and (D) presence of non-calcified plaque (NCP) or mixed plaque (MP) in 2 or more segments of the coronary tree and presence or absence of PD.</p

Improved prediction of adverse cardiac events with integration of cardiac computed tomography (CT) and single-photon emission computed tomography (SPECT).

<p>Comparison of the annual event rate according to (A) increasing coronary artery calcium score (CACS), (B) worsening diameter stenosis (DS), (C) presence of non-calcified plaque (NCP), (D) mixed plaque (MP), and (E) calcified plaque (CP) between patients with and without perfusion defect (PD) on SPECT.</p

Incremental prognostic value of cardiac CT findings for adverse cardiac event.

<p>Incremental prognostic value of cardiac CT findings for adverse cardiac event.</p

The occurrence of adverse cardiac event according to cardiac CT and myocardial SPECT.

<p>The occurrence of adverse cardiac event according to cardiac CT and myocardial SPECT.</p